As much as I appreciate people posting research on the potential of products in Amarantus portfolio, the most important factor at this moment is whether management is able to get the money to start ESS trials (since all else is on hold). If not, Amarantus will continue to exist at the expense of regular share holders again. Fred at IR said (via email) that all negotiating parties are still on the table.